Zivo Bioscience, Inc. SEC filings ZIVO
Zivo Bioscience, Inc. has 757 filings in SEC EDGAR's recent list, going back to Apr 20, 2000. Its latest annual report, Form ARS, was filed on Apr 25, 2025 for the period ended Dec 31, 2024. The latest quarterly report (Form 10-Q) was filed on Nov 14, 2025, covering the quarter ended Sep 30, 2025. The most recent current report (Form 8-K) was filed on Mar 30, 2026 (officer or director change, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Apr 25, 2025 | Apr 25, 2025 |
| DEFA14A | Additional proxy material | Apr 25, 2025 | — |
| DEFA14A | Additional proxy material | Apr 26, 2024 | — |
| DEF 14A | Proxy statement | Apr 26, 2024 | Jun 11, 2024 |
| DEF 14A | Proxy statement | Apr 28, 2023 | Jun 12, 2023 |
| DEF 14A | Proxy statement | Jul 5, 2022 | Jul 28, 2022 |
| DEFA14A | Additional proxy material | Sep 22, 2021 | — |
| DEF 14A | Proxy statement | Sep 13, 2021 | Oct 12, 2021 |
| DEF 14A | Proxy statement | Apr 29, 2020 | Apr 29, 2020 |
| DEFA14A | Additional proxy material | Apr 29, 2019 | — |
| DEF 14A | Proxy statement | Mar 19, 2019 | Mar 18, 2019 |
| PRE 14A | Preliminary proxy statement | Feb 28, 2019 | Feb 28, 2019 |
| DEF 14A | Proxy statement | Sep 27, 2018 | Sep 26, 2018 |
| PRE 14A | Preliminary proxy statement | Apr 30, 2018 | Apr 27, 2018 |
| DEF 14A | Proxy statement | Oct 3, 2017 | Oct 3, 2017 |
| PRE 14A | Preliminary proxy statement | Sep 21, 2017 | Sep 20, 2017 |
| PRE 14A | Preliminary proxy statement | Apr 28, 2017 | Apr 28, 2017 |
| DEF 14A | Proxy statement | Oct 3, 2016 | Sep 30, 2016 |
| PRE 14A | Preliminary proxy statement | Sep 21, 2016 | Sep 21, 2016 |
| DEF 14A | Proxy statement | Sep 15, 2016 | Sep 14, 2016 |
| DEF 14A | Proxy statement | Apr 29, 2016 | Apr 29, 2016 |
| DEF 14A | Proxy statement | Apr 30, 2015 | Apr 30, 2015 |
| PRE 14A | Preliminary proxy statement | Apr 21, 2015 | Apr 21, 2015 |
| DEF 14A | Proxy statement | Sep 5, 2014 | Sep 5, 2014 |
| PRE 14A | Preliminary proxy statement | Aug 22, 2014 | Aug 22, 2014 |
| DEF 14A | Proxy statement | Apr 30, 2014 | Apr 30, 2014 |
| DEF 14A | Proxy statement | Apr 26, 2013 | Apr 26, 2013 |
| DEFA14A | Additional proxy material | Jun 29, 2012 | — |
| DEF 14A | Proxy statement | Jun 22, 2012 | Jun 21, 2012 |
| PRE 14A | Preliminary proxy statement | Jun 5, 2012 | Jun 4, 2012 |
| DEF 14A | Proxy statement | May 13, 2010 | May 13, 2010 |
| DEF 14C | Information statement | Dec 18, 2003 | Dec 18, 2003 |
Showing 32 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ZIVO (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Bloomfield Hills, MI
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1101026
- Former names
- HEALTH ENHANCEMENT PRODUCTS INC (until Oct 16, 2014); WESTERN GLORY HOLE INC (until Jan 26, 2004)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.